Johnson & Johnson (J&J) has offered to pay as much as $5.5bn (£4.14bn) to resolve tens of thousands of lawsuits in the US alleging that its baby powder and other products containing talcum cause ovarian cancer.

The proposed landmark settlement aims to close a long-running legal battle that has weighed on the New Jersey-based healthcare giant for years.

J&J has denied that its talc-based products caused cancer and has changed the formula of its widely used baby powder.

Erik Haas, the firm’s vice president of litigation said on Monday that the allegations are “meritless” and that J&J was willing to settle in order to finally resolve the matter.

J&J said the settlement would cover about 76,000 cases, totalling most of the remaining talc-related claims. The firm said it will offer up to $3bn next year, with no additional payments due before 2028, it said.

The proposal must be accepted by legal firms representing 95% of the ovarian cancer claims in state and federal courts before it can be finalised, the J&J said.

Haas said in a statement that the company is confident that it would have “ultimately prevailed with further litigation” just as it has in the majority of cases heard in court to date.

He added that the proposed resolution “allows the company to put this matter behind it” and enable J&J to “remain focused on its mission to develop medicines and devices that save lives”.

J&J’s former consumer health business, Kenvue, holds liability for Johnson’s baby powder outside North America.

Kenvue – which owns well-known brands including Band-Aid, Listerine, and Calpol – was spun off from J&J in 2022.

Lawsuits against J&J over its talc-based baby powder started as early as 2009.

Earlier in July, a federal court handed the firm a victory by questioning individual plaintiffs’ ability to show that talc was the direct cause of their ovarian cancer.